{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T07:10:02Z","timestamp":1756537802070,"version":"3.44.0"},"reference-count":32,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Environ Pathol Toxicol Oncol"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Despite advancements in systemic therapy, the mortality rate for patients with metastatic melanoma remains around 70&amp;#37;, underscoring the imperative for alternative treatment strategies. Through the establishment of a chemoresistant melanoma model and a subsequent drug investigation, we have identified pacritinib, a medication designed for treating myelofibrosis and severe thrombocytopenia, as a potential candidate to overcome resistance to melanoma therapy. Our research reveals that pacritinib, administered at clinically achievable concentrations, effectively targets dacarbazine-resistant melanoma cells by suppressing IRAK1 rather than JAK2. Notably, melanoma-resistant cells exhibit elevated p-IRAK1 levels, while there is no discernible difference in p-JAK2 levels between sensitive and resistant cells. Additionally, analysis of melanoma patients indicates a higher expression of IRAK1, correlating with a significantly improved survival rate. Furthermore, the depletion of IRAK1 not only reduces cell viability in melanoma cells but also enhances the effectiveness of dacarbazine treatment. In a dacarbazine-resistant melanoma model, pacritinib demonstrates significant inhibition of tumor growth in mice, leading to enhanced overall survival. In the dacarbazine-sensitive melanoma model, the combination of pacritinib and dacarbazine is more effective than dacarbazine alone in reducing tumor growth and improving overall survival in mice. In summary, our findings highlight IRAK1 as a promising therapeutic target to overcome melanoma resistance, and pacritinib emerges as a valuable addition to the treatment armamentarium for melanoma.\n<\/p>","DOI":"10.1615\/jenvironpatholtoxicoloncol.2024053298","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:32:52Z","timestamp":1736764372000},"page":"51-61","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of Interleukin-1 Receptor-Associated Kinase-1 by Pacritinib Is a Therapeutic Strategy to Overcome Melanoma Resistance"],"prefix":"10.1615","volume":"44","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Bolick NL, Geller AC. Epidemiology of melanoma. Hematol Oncol Clin North Am. 2021;35(1):57-72.","DOI":"10.1016\/j.hoc.2020.08.011"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572-6.","DOI":"10.1155\/2014\/843214"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Natarelli N, Aleman SJ, Mark IM, Tran JT, Kwak S, Botto E, Aflatooni S, Diaz MJ, Lipner SR. A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals. 2024;17(2).","DOI":"10.3390\/ph17020214"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Namikawa K, Nakano E, Ogata D, Yamazaki N. Long-term survival with systemic therapy in the last decade: Can melanoma be cured? J Dermatol. 2024;51(3):343-52.","DOI":"10.1111\/1346-8138.17147"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Winder M, Viros A. Mechanisms of drug resistance in melanoma. Handb Exp Pharmacol. 2018;249:91-108.","DOI":"10.1007\/164_2017_17"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Manzano JL, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E, Martinez-Cardus A. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016;4(12):237.","DOI":"10.21037\/atm.2016.06.07"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Al Hmada Y, Brodell RT, Kharouf N, Flanagan TW, Alamodi AA, Hassan SY, Shalaby H, Hassan SL, Haikel Y, Megahed M, Santourlidis S, Hassan M. Mechanisms of melanoma progression and treatment resistance: Role of cancer stem-like cells. Cancers. 2024;16(2).","DOI":"10.3390\/cancers16020470"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008;7(11):3642-53.","DOI":"10.1158\/1535-7163.MCT-08-0582"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007;13(15 Pt 1):4565-74.","DOI":"10.1158\/1078-0432.CCR-07-0274"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Bennett J, Starczynowski DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Curr Opin Hematol. 2022;29(1):8-19.","DOI":"10.1097\/MOH.0000000000000693"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Pereira M, Gazzinelli RT. Regulation of innate immune signaling by IRAK proteins. Front Immunol. 2023;14:1133354.","DOI":"10.3389\/fimmu.2023.1133354"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, Vandenburg Y, Xiao H, Qian W, Hamilton T, Min B, Sen G, Gilmour R, Li X. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med. 2007;204(5):1025-36.","DOI":"10.1084\/jem.20061825"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Vollmer S, Strickson S, Zhang T, Gray N, Lee KL, Rao VR, Cohen P. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. Biochem J. 2017;474(12):2027-38.","DOI":"10.1042\/BCJ20170097"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, McKenna C, Bansal N, Ochoa A, Davila E. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012;72(23):6209-16.","DOI":"10.1158\/0008-5472.CAN-12-0337"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015;6:8746.","DOI":"10.1038\/ncomms9746"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Liu L, Liu S, Deng P, Liang Y, Xiao R, Tang LQ, Chen J, Chen QY, Guan P, Yan SM, Huang X, Hong JH, Chen J, Sun Y, Teh BT, Yu Q, Mai HQ, Tan J. Targeting the IRAK1-S100A9 axis overcomes resistance to paclitaxel in nasopharyngeal carcinoma. Cancer Res. 2021;81(5):1413-25.","DOI":"10.1158\/0008-5472.CAN-20-2125"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol. 2016;8:11-9.","DOI":"10.2147\/JEP.S110702"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ke F, Yu J, Chen W, Si X, Li X, Yang F, Liao Y, Zuo Z. The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt\/AMPK\/mTOR inhibition. Biochem Biophys Res Commun. 2018;504(2):374-9.","DOI":"10.1016\/j.bbrc.2018.06.049"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Vincent KM, Postovit LM. Investigating the utility of human melanoma cell lines as tumour models. Oncotarget. 2017;8(6):10498-509.","DOI":"10.18632\/oncotarget.14443"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Li Y, Shah RB, Sarti S, Belcher AL, Lee BJ, Gorbatenko A, Nemati F, Yu H, Stanley Z, Rahman M, Shao Z, Silva JM, Zha S, Sidi S. A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR\/IL-1R signaling. Science Signal. 2023;16(816):eadh3449.","DOI":"10.1126\/scisignal.adh3449"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018;32(11):2374-87.","DOI":"10.1038\/s41375-018-0112-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Rajpoot S, Wary KK, Ibbott R, Liu D, Saqib U, Thurston TLM, Baig MS. TIRAP in the mechanism of inflammation. Front Immunol. 2021;12:697588.","DOI":"10.3389\/fimmu.2021.697588"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, Alesse E, Zazzeroni F. Life, death, and autophagy in cancer: NF-kB turns up everywhere. Cell Death Dis. 2020;11(3):210.","DOI":"10.1038\/s41419-020-2399-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ueda Y, Richmond A. NF-kB activation in melanoma. Pigment Cell Res. 2006;19(2):112-24.","DOI":"10.1111\/j.1600-0749.2006.00304.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs. best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol. 2018;4(5):652-9.","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Exp Rev Hematol. 2022;15(8):671-84.","DOI":"10.1080\/17474086.2022.2112565"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Jensen KV, Cseh O, Aman A, Weiss S, Luchman HA. The JAK2\/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017;12(12):e0189670.","DOI":"10.1371\/journal.pone.0189670"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, Kiura K, Takigawa N. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung cancer. Exp Cell Res. 2016;344(2):194-200.","DOI":"10.1016\/j.yexcr.2016.05.008"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Doheny D, Sirkisoon S, Carpenter RL, Aguayo NR, Regua AT, Anguelov M, Manore SG, Arrigo A, Jalboush SA, Wong GL, Yu Y, Wagner CJ, Chan M, Ruiz J, Thomas A, Strowd R, Lin J, Lo HW. Combined inhibition of JAK2-STAT3 and SMO-GLI1\/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. Oncogene. 2020;39(42):6589-605.","DOI":"10.1038\/s41388-020-01454-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Mao F, Gao L, Liu L, Tang Y. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2\/STAT pathway. J Chemother. 2023:1-11.","DOI":"10.1080\/1120009X.2023.2274700"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2\/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drug. 2020;38(2):340-9.","DOI":"10.1007\/s10637-019-00786-4"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC. Pacritinib to inhibit JAK\/STAT signaling in refractory metastatic colon and rectal cancer. J Gastrointest Oncol. 2017;8(6):985-9.","DOI":"10.21037\/jgo.2017.08.16"}],"container-title":["Journal of Environmental Pathology, Toxicology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/28b737c075387f7b\/JEP(T)-53298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:48:41Z","timestamp":1756536521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/0ff459a57a4c08d0,7f8ae079718bb327,28b737c075387f7b.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/jenvironpatholtoxicoloncol.2024053298","relation":{},"ISSN":["0731-8898"],"issn-type":[{"type":"print","value":"0731-8898"}],"subject":[],"published":{"date-parts":[[2025]]}}}